Belite Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-31.63	-31.63	-12.65	-9.67	-5.75
Depreciation & Amortization	0.4	0.4	0.2	0.03	0.02
Share-Based Compensation	3.82	3.82	1.48	1.53	1.36
Other Operating Activities	-2.43	-2.43	-0.49	0.63	-0.07
Operating Cash Flow	-29.84	-29.84	-11.46	-7.47	-4.44
Capital Expenditures	-0.06	-0.06	-0.39	-0.06	-0.02
Investing Cash Flow	-0.06	-0.06	-0.39	-0.06	-0.02
Share Issuance / Repurchase	77.19	77.19	37.99	0.23	0.59
Debt Issued / Paid	0	0	0	0	-2.32
Other Financing Activities	-1.23	-1.23	-1.03	-0.82	29.79
Financing Cash Flow	75.96	75.96	36.96	-0.58	28.06
Exchange Rate Effect	0.01	0.01	-0.37	-0.16	0
Net Cash Flow	46.07	46.07	24.75	-8.27	23.6
Free Cash Flow	-29.9	-29.9	-11.85	-7.53	-4.46
Free Cash Flow Per Share	-1.12	-1.12	-0.59	-0.79	-0.51

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).